Research library / NAD+ (NR, NMN)

A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects

O Dollerup, B Christensen, M Svart, M Schmidt, K Sulek, S Ringgaard et al.. The American Journal of Clinical Nutrition. 2018.

Published 2026-10-15Sources checked 2026-10-151 sourceEverstack research teamHow we work

In plain language

12 weeks of 2,000 mg per day NR was safe but did not improve insulin sensitivity or body composition.

Limits

Small; specific population.

Source

doi.org/10.1093/ajcn/nqy132 · PubMed 29992272

Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack.